Sheikh Rayees Rafiq
CSIR – Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001
Dr. Rayees earned his PhD degree from CSIR-IIIM and SMVDU and conducted his postdoctoral research work at University of Illinois Chicago, USA. During his postdoctoral research he studied i) the counterbalancing mechanism that deactivates alveolar macrophage inflammatory signalling to prevent lethal lung edema, and ii) the signalling cascade that activates P. aeruginosa clearance in alveolar macrophages to prevent death from bacterial pneumonia.
He demonstrated that PAR2, a GPCR, induced cAMP generation in alveolar macrophages and suppresses activation NFAT, secondary to Ca2+ entry through TRPV4 channel and hence blocks the inflammatory signalling of alveolar macrophages which may otherwise lead to lethal pulmonary edema.
In another study, he showed that PAR2 expressed on mouse alveolar macrophages mediates the clearance of P. aeruginosa to prevent mortality from pneumonia. He showed that binding of P. aeruginosa to PAR2 elevated cAMP levels, activates Rac1 through PKA to form actin-rich protrusions and augment clearance of P. aeruginosa. These studies involved the use of highly efficient mouse models such as generation of mouse chimeras (bone marrow transplantation), in vivo gene delivery of PAR2, CREB, Rac1 (Q61L) cDNA in inflammation, infection and developmental biology mice models, adoptive transfer of PAR2+/+ or PAR2-/- and macrophages following clodronate induced macrophage depletion and mouse models of bacterial pneumonia. These studies also involved use of explicit cell biology techniques related to GPCR translocation, FRET imaging, live cell imaging, electroporation.
His scientific training during PhD programme at CSIR-IIIM was mainly focussed on drug development. He published several good impact research articles as lead author. During this tenure he learnt techniques related to general and advanced pharmacology, pharmacokinetics and pharmacodynamics. He gained special expertise over rodent invasive and non-invasive techniques during his PhD programme.
|PhD||Biotechnology||CSIR-IIIM / SMVDU, Jammu||2015|
|MSc||Biotechnology||HNB Garhwal University, Uttarakhand||2008|
|BSc||Biology,Chemsitry||University of Kashmir||2005|
|Ramalingaswami Fellow||Oct 2020-Present||CSIR-IIIM, Jammu|
|Posdoctoral research associate||Nov 2015-Aug 2020||University of Illinois Chicago, USA|
Area of Expertise
- GPCR and Calcium signalling in lung inflammation and infection
- Molecular pharmacology of inflammation
- Development of mouse models of respiratory diseases and inflammation
- Safety pharmacology
- Drug discovery
- Development of a new generation small molecule inhibitor to block TRPV4 mediated signaling in acute lung injury (PI-DBT)
|Rayees S, Joshi JC, Tauseef M, Anwar M, Baweja S, Rochford I, Joshi B, Hollenberg MD, Reddy SP, Mehta D.||PAR2-Mediated cAMP Generation Suppresses TRPV4-Dependent Ca2+ Signaling in Alveolar Macrophages to Resolve TLR4-Induced Inflammation.
|Rayees S, Joshi JC, Joshi B, Vellingiri V, Banerjee S, Mehta D.||Protease-activated receptor 2 promotes clearance of Pseudomonas aeruginosa infection by inducing cAMP-Rac1 signaling in alveolar macrophages.
|Joshi JC, Joshi B, Rochford I, Rayees S, Akhter MZ, Baweja S, Chava KR, Tauseef M, Abdelkarim H, Natarajan V, Gaponenko V, Mehta D.||SPHK2-Generated S1P in CD11b+ Macrophages Blocks STING to Suppress the Inflammatory Function of Alveolar Macrophages.
|Rochford I, Joshi JC, Rayees S, Anwar M, Akhter MZ, Yalagala L, Banerjee S, Mehta D.||Evidence for reprogramming of monocytes into reparative alveolar macrophages in vivo by targeting PDE4b.
|Yazbeck P, Tauseef M, Kruse K, Amin MR, Rayees S, Feske S, Komarova Y, Mehta D.||STIM1 Phosphorylation at Y361 Recruits Orai1 to STIM1 Puncta and Induces Ca2+ Entry.
|Rayees S, Mabalirajan U, Bhat WW, Rasool S, Rather RA, Panda L, Satti NK, Lattoo SK, Ghosh B, Singh G.||Therapeutic effects of R8, a semi-synthetic analogue of Vasicine, on murine model of allergic airway inflammation via STAT6 inhibition.
|Rayees S, Sharma R, Singh G, Najar IA, Singh A, Ahamad DB, Sharma SC, Tikoo MK, Gupta VK, Sangwan PL, Singh S, Koul S, Johri RK.||Acute, sub-acute and general pharmacological evaluation of 5-(3,4-methylenedioxyphenyl)-4-ethyl-2E,4E-pentadienoic acid piperidide (SK-20): a novel drug bioavailability enhancer.
|Environ. Toxicol. Pharmacol.|
|Rayees S, Kumar A, Rasool S, Kaiser P, Satti NK, Sangwan PL, Singh S, Johri RK, Singh G.||Ethanolic extract of Alternanthera sessilis (AS-1) inhibits IgE-mediated allergic response in RBL-2H3 cells.
|Majeed R, Hamid A, Sangwan PL, Chinthakindi PK, Koul S, Rayees S, Singh G, Mondhe DM, Mintoo MJ, Singh SK, Rath SK, Saxena AK.||Inhibition of phosphotidylinositol-3 kinase pathway by a novel naphthol derivative of betulinic acid induces cell cycle arrest and apoptosis in cancer cells of different origin.
2014, 5(10): e1459.
|Cell death & disease|
|Rayees S, Rochford I, Joshi JC, Joshi B, Banerjee S, Mehta D.||Macrophage TLR4 and PAR2 Signaling: Role in Regulating Vascular Inflammatory Injury and Repair.
Awards and Honours
- RamalingaSwami award (2020) from Department of Biotechnology, Government of India, 2020.
- Postdoctoral travel award by the American Physiological society (APS),Experimental biology 2018, San Diego, USA.
- Senior Research Fellow grant from Indian Council of Medical Research(ICMR), Government of India, 2013.
|Photo||Name||Area of intrest||Position||Education|
|Yassir Arfath||Ligand induced TRPV4 modulation, its cross talk and role inflammation||JRF-UGC|
|Tusharika Kotra||Lung injury/Lung inflammation- Mechanistic and therapeutic understanding||JRF- CSIR|